Antineoplastic AgentsChemotherapy, AdjuvantAntineoplastic Combined Chemotherapy ProtocolsRadiation InjuriesRadiation DosageRadiation, IonizingDose-Response Relationship, RadiationBreast NeoplasmsCombined Modality TherapyMedical OncologySEER ProgramRadiation ToleranceNeoplasm StagingRadiotherapyRadiotherapy DosageTreatment OutcomeNeoplasmsDoxorubicinRadiationCisplatinCell Line, TumorDrug Screening Assays, AntitumorRadiation OncologyRadiation ProtectionRadiotherapy, ConformalRadiotherapy, Intensity-ModulatedRadiation MonitoringRadiotherapy, AdjuvantDose FractionationDrug Resistance, NeoplasmRetrospective StudiesApoptosisAntineoplastic Agents, PhytogenicRadiation PneumonitisRadiotherapy Planning, Computer-AssistedAge FactorsEtoposideUnited StatesBrachytherapyCell SurvivalRadiation-Sensitizing AgentsAntibiotics, AntineoplasticPaclitaxelBrain NeoplasmsNeoplasm Recurrence, LocalLung NeoplasmsCohort StudiesRadiometryDisease-Free SurvivalNeoplasms, Radiation-InducedSurvival AnalysisGamma RaysCyclophosphamideRadiation Injuries, ExperimentalDrug Delivery SystemsXenograft Model Antitumor AssaysRadiosurgeryTime FactorsTumor Cells, CulturedMice, NudeSurvival RateCranial IrradiationHead and Neck NeoplasmsPrognosisAdenocarcinomaCosmic RadiationCamptothecinDNA DamageDrug CarriersVinblastineDose-Response Relationship, DrugRadiotherapy, Computer-AssistedAntimetabolites, AntineoplasticCarcinoma, Squamous CellNeoadjuvant TherapyBleomycinCell ProliferationAntineoplastic Agents, AlkylatingParticle AcceleratorsFollow-Up StudiesDrug Administration ScheduleRadiation-Protective AgentsCarboplatinRadiotherapy, Image-GuidedProstatic NeoplasmsOrganoplatinum CompoundsRadiotherapy, High-EnergyMethotrexateRadiodermatitisEllipticinesDrug Resistance, MultipleBackground RadiationChemoradiotherapyP-GlycoproteinDacarbazineFluorouracilTumor BurdenCarcinoma, Non-Small-Cell LungClinical Trials as TopicUltraviolet Rays